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Case control study
Older women who use bisphosphonate for longer than 
5 years may have increased odds of a subtrochanteric or 
femoral shaft fracture, but absolute risk is low
Bo Abrahamsen
Context
It is now recognised that fractures of the subtrochanteric 
femur or femoral shaft (ST/FS fractures) can be divided 
radiologically into (1) typical fractures and (2) atypical 
fractures. The latter appear to be rare in patients untreated 
by bisphosphonates. In this new study, Park-Wyllie et al 
used Ontario claims data to investigate the association 
between the amount of bisphosphonates taken and the 
risk of ST/FS fractures.
Methods
The study was a nested 5:1 case-control study, linking pre-
scriptions with hospitalisations, physician service claims 
and death certifi cates. Women aged 68 years or older 
who fi lled prescriptions for bisphosphonates at least once 
over a 6-year period were included. Those with malig-
nant disease in the past 10 years, specifi c bone diseases 
or secondary causes of osteoporosis (past 5 years) and 
osteoporosis treatment in the past year were excluded, 
providing 205 466 women for study.
Cases were defi ned as fi rst ST/FS fracture, excluding 
fractures treated exclusively with hip replacement and 
fractures due to vehicle accidents and falls from a height. 
In a secondary analysis, cases were defi ned as those with 
a classic osteoporotic fracture (femoral neck or intertro-
chanteric hip, FN/IT). Another secondary analysis focused 
on long-term users of bisphosphonates.
Bisphosphonate exposure was categorised as long-
term use (≥5 years), intermediate use (between 3 and 5 
years), short-term use (100 days to 3 years) and a refer-
ence category for ‘transient use’ (<100 days).
Analysis was conditional logistic regression with adjust-
ment for socioeconomic status (by postcode), key other 
medications, count of medications, comorbidities, physician 
claims and existence of a bone mineral measurement.
Findings
In 716 patients with new ST/FS fractures, bisphospho-
nate exposure was transient in 5.9%, short term in 48.7%, 
intermediate in 28.5% and long term in 16.9%. In 3580 
bisphosphonate-treated controls who did not sustain such 
fractures, exposure was transient in 6.1%, short term in 
51.2%, intermediate in 29.9% and long term in 12.9%. 
Logistic regression analysis found no increased risk in 
the short term and intermediate exposure categories, but 
increased risk in the long-term exposed category with an 
adjusted OR of 2.74 (95% CI 1.25 to 6.02). In patients treated 
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for more than 5 years, 64% of such fractures could statisti-
cally be explained by long-term use. Approximately one in 
ten ST/FS fractures in users could be avoided if no patient 
was treated for more than 5 years. For FN/IT fractures – 
classic osteoporotic fracture sites where bisphosphonates 
are known to reduce risk – the adjusted OR for long-term 
use of bisphosphonates was 0.76 (95% CI 0.63 to 0.93).
Commentary
Including all ST/FS fractures as the condition of interest 
in this study means that risks of their occurrence that were 
identifi ed mark an upper boundary because these fractures 
include both atypical and osteoporotic fractures. A gradient 
in risk could suggest a causal relationship. If patients with 
long-term exposure to bisphosphonates are more likely 
to fracture then bisphosphonates could be the culprit. But 
like any association, dose-response relationships can be 
spurious. For example, patients who take bisphosphonates 
for a long period of time may do so because they have 
unusually strong risk factors for fracture. Patients who 
adhere faithfully to bisphosphonates may also adhere to 
other medications that could predispose them to fractures. 
Glucocorticoids and proton pump inhibitors (PPI) were 
used by a large proportion of patients in this study and 
in case reports of radiologically adjudicated atypical frac-
tures. PPIs have been linked to increased fracture risk1 and 
to attenuation of the effect of alendronate.2 The fi ndings 
here were adjusted for baseline PPI and glucocorticoid use, 
though entering these covariates in a time-dependent Cox 
proportional hazards analysis might be more informative. 
Bisphosphonates cause dyspepsia so many patients using 
PPIs might not have done so at baseline.
The design of this study, a nested case-control study, 
did not allow calculation of absolute risks and appraisal 
of competing risks (eg, death) that could have been cal-
culated as information from the full cohort was avail-
able. Also, there were large differences between cases and 
controls. For example, 70% of cases had prior fractures, 
67% were ‘fallers’, and 45% used PPIs; among controls, 
proportions with these characteristics were 24%, 6% and 
36%, respectively. Unmeasured confounders may have 
been similarly unbalanced. One may compare the known 
effects of bisphosphonates on hip fractures with data from 
the current study. Interestingly, although 3 years of treat-
ment in clinical trials reduced the risk of hip fracture by 
40–50% in conservative intention-to-treat analyses,3 4 the 
current study reports a risk reduction of only 14% after 
3–5 years. Some patients in the current study would 
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not have been eligible for participation in trials due to 
concomitant diseases, but the discrepancy in risk reduc-
tion raises questions about the current analysis that are 
worthy of further study. Observational studies may not 
reproduce effects observed in clinical trials. For example, 
US claims data5 showed no difference in the risk of ST/
FS fractures between bisphosphonate users and patients 
treated for osteoporosis with weaker antiresorptive drugs 
not believed to carry a risk of atypical femur fractures.
Atypical femur fractures are too rare for reliable risk 
information to be drawn from randomised controlled 
trials (RCTs); the study by Park-Wyllie et al provides 
new information on the upper boundary of risk seen in 
patients who have received prolonged treatment.
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